Literature DB >> 18162113

Bayesian optimal design for phase II screening trials.

Meichun Ding1, Gary L Rosner2, Peter Müller2.   

Abstract

Most phase II screening designs available in the literature consider one treatment at a time. Each study is considered in isolation. We propose a more systematic decision-making approach to the phase II screening process. The sequential design allows for more efficiency and greater learning about treatments. The approach incorporates a Bayesian hierarchical model that allows combining information across several related studies in a formal way and improves estimation in small data sets by borrowing strength from other treatments. The design incorporates a utility function that includes sampling costs and possible future payoff. Computer simulations show that this method has high probability of discarding treatments with low success rates and moving treatments with high success rates to phase III trial.

Entities:  

Mesh:

Year:  2007        PMID: 18162113      PMCID: PMC3075947          DOI: 10.1111/j.1541-0420.2007.00951.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   1.701


  13 in total

1.  Optimal designs for evaluating a series of treatments.

Authors:  D H Leung; Y G Wang
Journal:  Biometrics       Date:  2001-03       Impact factor: 2.571

2.  Screening designs for drug development.

Authors:  David Rossell; Peter Müller; Gary L Rosner
Journal:  Biostatistics       Date:  2006-10-09       Impact factor: 5.899

3.  Practical Bayesian guidelines for phase IIB clinical trials.

Authors:  P F Thall; R Simon
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

4.  Approaches for optimal sequential decision analysis in clinical trials.

Authors:  B P Carlin; J B Kadane; A E Gelfand
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

5.  Optimal two-stage design for a series of pilot trials of new agents.

Authors:  T J Yao; E S Venkatraman
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

6.  Optimal sample size for a series of pilot trials of new agents.

Authors:  T J Yao; C B Begg; P O Livingston
Journal:  Biometrics       Date:  1996-09       Impact factor: 2.571

7.  An optimal design for screening trials.

Authors:  Y G Wang; D H Leung
Journal:  Biometrics       Date:  1998-03       Impact factor: 2.571

8.  Bayesian interim analysis of phase II cancer clinical trials.

Authors:  D F Heitjan
Journal:  Stat Med       Date:  1997-08-30       Impact factor: 2.373

9.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

10.  A bayesian approach to the design of phase II clinical trials.

Authors:  R J Sylvester
Journal:  Biometrics       Date:  1988-09       Impact factor: 2.571

View more
  9 in total

1.  Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.

Authors:  Wei Jiang; Jo A Wick; Jianghua He; Jonathan D Mahnken; Matthew S Mayo
Journal:  J Biopharm Stat       Date:  2017-11-27       Impact factor: 1.051

2.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

3.  Bayesian adaptive phase II screening design for combination trials.

Authors:  Chunyan Cai; Ying Yuan; Valen E Johnson
Journal:  Clin Trials       Date:  2013-01-28       Impact factor: 2.486

4.  Bayesian Methods in Regulatory Science.

Authors:  Gary L Rosner
Journal:  Stat Biopharm Res       Date:  2019-10-29       Impact factor: 1.452

5.  Optimal Decision Stimuli for Risky Choice Experiments: An Adaptive Approach.

Authors:  Daniel R Cavagnaro; Richard Gonzalez; Jay I Myung; Mark A Pitt
Journal:  Manage Sci       Date:  2013-02       Impact factor: 4.883

6.  Estimating optimal dynamic treatment strategies under resource constraints using dynamic marginal structural models.

Authors:  Ellen C Caniglia; Eleanor J Murray; Miguel A Hernán; Zach Shahn
Journal:  Stat Med       Date:  2021-06-29       Impact factor: 2.497

Review 7.  Decision-theoretic designs for small trials and pilot studies: A review.

Authors:  Siew Wan Hee; Thomas Hamborg; Simon Day; Jason Madan; Frank Miller; Martin Posch; Sarah Zohar; Nigel Stallard
Journal:  Stat Methods Med Res       Date:  2015-06-05       Impact factor: 3.021

8.  Decision-theoretic designs for a series of trials with correlated treatment effects using the Sarmanov multivariate beta-binomial distribution.

Authors:  Siew Wan Hee; Nicholas Parsons; Nigel Stallard
Journal:  Biom J       Date:  2017-07-26       Impact factor: 2.207

9.  Optimal designs for phase II/III drug development programs including methods for discounting of phase II results.

Authors:  Stella Erdmann; Marietta Kirchner; Heiko Götte; Meinhard Kieser
Journal:  BMC Med Res Methodol       Date:  2020-10-09       Impact factor: 4.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.